Market Intelligence, Clinical Progress, and High-Purity Reagents for Tight Junction Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLDN4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLDN4 ECL1-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CLDN4 Products |
| Gene Delivery | CLDN4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Preserves native 4-pass transmembrane conformation. |
View CLDN4 Products |
| Benchmark Ab | Anti-CLDN4 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View CLDN4 Products |
| Validator | CLDN4 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View CLDN4 Products |
| Related Target A | CLDN3 High homology counter-screening antigen to avoid off-target toxicity. |
View CLDN3 Products |
| Related Target B | CLDN6 Oncofetal tight junction protein; crucial for selectivity profiling. |
View CLDN6 Products |
| Related Target C | CLDN18.2 Lineage-matched gastric cancer target for comparative therapeutic mapping. |
View CLDN18.2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CLDN3/CLDN9 Subfamily Cross-Reactivity | Sequence-verified ECL1 and ECL2 recombinant proteins of CLDN3/4/6/9 for precise selectivity ELISA. |
| Conformational Epitope Loss in Soluble Formats | High-titer Lentivirus Premade Particles for stable cell line generation, enabling flow cytometry and cell-based binding. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) sequence-verified and HEK293 expressed. |
| False Positives | In vitro validated siRNA pool included for target-specific validation. |
Live CLDN4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLDN4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to T-cell engagers (TCEs) and Antibody-Drug Conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective epitopes to bypass systemic toxicity caused by cross-reactivity with normal tissue-expressed Claudins.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific / TCE | Zymeworks, Amgen | Ovarian Cancer, Pancreatic Cancer | Selectivity Screening (Need CLDN3/CLDN4/CLDN9 homolog panel) |
| ADC | Mersana Therapeutics | Solid Tumors, Gastric Cancer | Internalization Assay (Need Lentivirus-driven stable cell lines) |
| Monoclonal Ab | Academic / Biotech Consortia | Colorectal Cancer | Epitope Mapping (Need ECL1 vs ECL2 recombinant constructs) |